Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Novo Nordisk (NVO) says its obesity drug Ozempic improved walking distance for diabetes patients with peripheral artery ...

Novo Nordisk said Monday that it had entered into a license agreement with a Chinese company developing a competitor to ...

The two stocks have been trending in different directions for months. Here's what that says about the broader market.